Induzepam

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Induzepam

Property Description
Active Ingredient Clonazepam
Form Oral tablet, Solution
Pharmacological Class Benzodiazepine, Anticonvulsant
General Purpose Neurological stabilization, reduction of excitability
Origin Synthetic, Single-ingredient

Induzepam: Definition and Classification as a Benzodiazepine

Induzepam is a prescription-only medicine that utilizes the active ingredient, the International Nonproprietary Name (INN) substance, Clonazepam. This compound is chemically classified as a synthetic Benzodiazepine derivative. Clonazepam is categorized within the Benzodiazepine pharmacological class, distinguished by its general properties as an anticonvulsant and a Central Nervous System (CNS) depressant. This classification is associated with potent inhibitory activity in the CNS.

Clonazepam is recognized as a high-potency, long-acting agent within its class. The chemical formula for Clonazepam is C15H10ClN3O3, confirming its molecular structure as a distinct entity. Induzepam is a single-ingredient product, focusing its entire action profile on the effects of this specific compound.

Composition, Forms, and General Therapeutic Utility

The medication is available in several dosage forms, including the standard oral tablet, the orally disintegrating tablet, and a solution formulation, the latter of which is often utilized for rapid administration via intravenous (IV) or intramuscular (IM) routes.

The primary function of Induzepam is to promote neurological stability. It achieves this by modulating the activity of the major inhibitory neurotransmitter, Gamma-Aminobutyric Acid (GABA), which slows down excessive nerve signaling. This neurochemical action is utilized for the general therapeutic purpose of managing states characterized by high neuronal excitability, such as the sustained dampening of uncontrolled electrical discharges in the brain.

Regulatory References

  1. Benzodiazepine
  2. high-potency, long-acting
  3. Gamma-Aminobutyric Acid (GABA)

What side effects are possible with Induzepam?

Induzepam: Possible Side Effects and Safety Information

Official regulatory documents classify the possible side effects of Induzepam (Clonazepam) based on frequency and the physiological system affected, reflecting its documented action as a Central Nervous System (CNS) depressant. This section strictly describes the adverse reactions and safety constraints as published in government labeling.

Frequency-Classified Adverse Reactions

The most frequently encountered effects are related to CNS depression and are often dose-related:

  • Very Common: Sedation, Drowsiness, Fatigue, and impaired coordination (Ataxia).
  • Common: Dizziness, difficulty concentrating, confusion, depression, muscle weakness, and nausea. Certain behavioral changes, such as excitation or irritability, are also commonly documented.
  • Rare: Documented rare adverse reactions include blood disorders and severe hypersensitivity reactions like Anaphylaxis.

Serious Safety Concerns and Restrictions

Specific serious adverse reactions are documented in official prescribing information:

  1. Respiratory Depression: The risk of severe respiratory depression is noted, particularly when the medicine is used at high doses or concurrently with other CNS depressants.
  2. Drug Dependence: The potential for developing physical and psychological dependence is a significant long-term safety concern, with the risk increasing with the duration of exposure.
  3. Paradoxical Reactions: Reactions such as aggression, hostility, or agitation, which are documented to occur.

Safety notes for specific populations include an increased susceptibility for older adults to effects like dizziness and ataxia, which raises the risk of falls. Furthermore, the medicine is explicitly contraindicated in individuals with severe hepatic (liver) impairment due to safety considerations outlined in the official label.

Overdose and Emergency Response

Overdose and When to Seek Help

Induzepam belongs to a class of medications for which abuse, misuse, and addiction can lead to serious outcomes, including overdose or death. The risk of severe central nervous system (CNS) and respiratory depression is significantly increased when this medication is combined with other substances.

Documented Overdose Symptoms

An Induzepam overdose typically manifests as severe CNS depression. Documented presentations include:

  • Profound sedation
  • Respiratory depression (severely slowed or shallow breathing)
  • Coma
  • Death

Serious adverse outcomes are strongly associated with the concomitant use of other Central Nervous System (CNS) depressants, such as opioids or alcohol, as well as the use of doses that are greater than prescribed.

Urgent Action Required

Immediate medical attention is necessary if you or someone else exhibits signs of an overdose. Do not wait for symptoms to worsen.

You must call emergency services (e.g., 911) or go to the nearest emergency room immediately if any of the following serious side effects occur:

  • Trouble breathing or severely slowed respiration.
  • Seizures.
  • Inability to wake the person up (unresponsiveness).

Therapeutic Uses of Induzepam

What Induzepam Treats: Main Uses and Benefits

Induzepam is commonly used across conditions presenting with acute episodes and may provide support that helps ease the overall symptom burden. It is applied across therapeutic domains where additional symptomatic support is needed, addressing groups of symptoms that may appear suddenly or intensify over time.

Managing Acute Episodic Symptoms

Induzepam is commonly used across conditions characterized by recurrent or episodic manifestations, particularly those involving symptoms of increased neurological or muscular activity. It is relevant in clinical settings for situations like certain seizure types (such as Lennox-Gastaut syndrome and myoclonic seizures) where supportive symptom management is appropriate. It may assist with maintaining functional stability during phases when symptoms become more noticeable.

Providing Short-Term Support for Panic and Intense Anxiety

This medication is considered relevant in contexts marked by increased discomfort or tension, applied in conditions where symptoms may intensify temporarily, such as those associated with Panic Disorder. It is used for managing symptoms that interfere with daily comfort, including unexpected panic attacks and associated physiological strain. May provide supportive relief when symptoms interfere with routine activities, which contributes to improved comfort during periods of heightened symptoms.


Quick Fact: Relevant for Symptoms related to heightened physiological activity


Regulatory References

  1. NIH DailyMed Drug Information

Eligibility and Restrictions for Use

Population Eligibility and Contraindications

Official regulatory labeling strictly defines specific populations who can and cannot use Induzepam (Clonazepam).

The medicine is absolutely contraindicated and must not be used by patients with a history of benzodiazepine hypersensitivity or those diagnosed with significant liver disease, severe hepatic impairment, or acute narrow-angle glaucoma. Use is also prohibited in patients with severe respiratory or acute pulmonary insufficiency.

Eligibility is established for adults across both seizure disorders and panic disorder. For pediatric patients, use is established for seizure disorders, but safety and efficacy for panic disorder have not been established.

Use requires caution in several populations. This includes older adults due to increased sensitivity, patients with renal impairment, and those with a history of drug or alcohol dependence or depression. Regulatory documents state that use during pregnancy is permitted only when clinical benefits outweigh the risk, and it is generally not recommended for women who are breastfeeding as it is excreted into human milk.

What should I know about interactions with other medicines?

Induzepam Interactions with Other Medicines and Products

This section outlines interactions for Induzepam (Clonazepam) as documented in authoritative government regulatory sources. These interactions describe constraints and requirements for use when co-administered with other substances.

Official Contraindicated Combinations

Certain combinations are formally prohibited due to severe risks, as stated in prescribing information:

Substance/Condition Regulatory Classification
Opioids Contraindicated (Risk of profound sedation, respiratory depression, coma, and death)
Alcohol (Ethanol) Contraindicated (Risk of severe sedation, respiratory, and cardiovascular depression)
Significant Liver Disease Contraindicated (Due to impaired elimination)

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interactions often involve additive effects or changes in Induzepam's concentration:

  • Central Nervous System (CNS) Depressants: Combining Induzepam with other CNS depressants, such as certain antidepressants, antipsychotics, hypnotics, and anxiolytics, increases the risk of additive CNS depressant effects, including severe sedation.
  • CYP3A4 Modifiers: Strong CYP3A4 inducers (e.g., Phenytoin, Carbamazepine, Phenobarbital) may reduce Induzepam's plasma concentrations. Conversely, strong CYP3A4 inhibitors (e.g., Atazanavir) may increase Induzepam's plasma levels, potentially leading to increased toxicity.
  • Antagonists: Administration of the benzodiazepine antagonist Flumazenil may precipitate acute withdrawal reactions, including seizures.

Population-Specific Considerations

Regulatory documents advise caution for specific populations. For instance, elderly or debilitated patients may require reduced dosing, and the use of Induzepam is contraindicated in those with significant liver disease.

Mechanism of Action

Modulating Central Inhibitory Signaling

Induzepam acts by enhancing GABA-A receptor activity in the central nervous system. It functions as a positive allosteric modulator, binding to a site distinct from the neurotransmitter GABA. This molecular interaction boosts the influx of negative chloride ions into the neuron, thereby increasing the intrinsic inhibitory tone across neuronal pathways.

Regulating Signal Transduction Cascades

The resulting cellular change initiates a rapid signal transduction cascade by hyperpolarizing target neurons. This hyperpolarization limits the capacity of the neuron to propagate electrical signals. This mechanistic interference affects neuronal systems characterized by heightened pathway activation, adjusting the excitability threshold within these circuits.

Influencing Physiological Signaling Patterns

The mechanism involves the modulation of specific pathways associated with dysregulated physiological processes. This occurs by limiting the spread of excessive neuronal excitability across networks. This modulation ultimately influences the signaling patterns within targeted pathways, thereby altering the activity of systems associated with overactive physiological responses.

Dosage and Administration Information

Induzepam is administered via the oral route using tablets, orally disintegrating tablets (ODT), or a liquid solution. Administration can occur with or without food. Usage is typically structured around a titration phase, where treatment begins with a low dose and is increased incrementally to reach a stable maintenance level.

For adult seizure disorders, the initial prescribed daily amount is typically 1.5 mg, usually divided into three administrations. The dose is then increased in small increments, such as 0.5 mg to 1 mg every three days, with the total daily dose not exceeding 20 mg. For panic disorder, the initial dose is commonly 0.25 mg taken twice daily, with a maximum dose of 4 mg/day.

The timing of administration is often adjusted over the course of treatment. During the initial phase, the total daily quantity is divided. If doses are unequal, it is generally practiced that the largest amount should be taken before retiring (at bedtime). Specific instructions govern the different forms: the oral solution must be measured using a provided calibrated device, and the ODT must be handled with dry hands before placing it on the tongue.

Dosing requires adjustment for specific patient groups; for instance, older adults are generally started on a lower initial dose, sometimes not exceeding 0.5 mg/day. Should the use of Induzepam be concluded, the medication is gradually withdrawn by slowly reducing the dose over several days to avoid immediate cessation effects. If a regularly scheduled dose is missed, the general approach is to skip the missed dose and resume the schedule at the next designated time.

Recent Clinical Evidence

Research evidence / Overview of studies for Induzepam


Evidence for Managing Seizure Disorders

Research exploring Induzepam was studied for seizure disorders, such as Lennox-Gastaut syndrome and myoclonic seizures, primarily using short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time and monitored measurements of seizure counts and, in some cases, whether seizure cessation was observed. The populations studied included both children and adults, with a specific focus on individuals facing treatment-resistant epilepsy.

Research highlights changes measured during the study period, focusing on seizure frequency over initial follow-up periods, typically lasting 9 to 12 weeks. The evidence level for this specific clinical context is generally categorized as High, based on the studies that examined acute management.

Long-term outcomes are not well characterized. A key limitation noted in the research is the documented pattern where tolerance (a diminished response to the medicine) may be observed developing in a subset of patients. This change was observed in some studies within the initial three months of continuous use. Long-term effects are not fully established by controlled studies, although some extended observational data has been collected, contributing to the broader evidence landscape.


Evidence for Managing Panic Disorder

The research for Induzepam in the management of Panic Disorder relies heavily on short-term, double-blind, placebo-controlled Randomized Controlled Trials (RCTs). These trials were applied in studies examining short-term or episodic symptom patterns, primarily involving adult outpatients. Studies monitored measurements related to the frequency of panic attacks and used patient-reported outcomes describing perceived discomfort and overall clinical status.

Research highlights changes measured during the study period, which typically lasted between six and nine weeks. The findings describe patterns observed in the studies, which focused on outcomes reflecting daily functioning or activity level. The evidence level for the short-term trials is generally categorized as High.

Evidence for long-term use remains limited. Follow-up durations were limited, meaning controlled data providing insight into long-term outcomes (beyond the initial nine weeks) are not fully established. A challenge noted in the research is that the potential for physical dependence was observed in some studies, which complicates the assessment of sustained management strategies.


Context of Evidence for Other Clinical Situations

Induzepam was evaluated in research exploring temporary physiological imbalance, such as studies focusing on acute mania. These research scenarios involved Randomized Controlled Trials, often comparing the medicine against active comparators. Studies monitored outcomes capturing phases of heightened symptom activity and the need for other "rescue" medications.


What is Still Uncertain About the Research Base

The research provides context but not individual predictions about symptom evolution. Evidence highlights what is known—and what is still uncertain—about Induzepam. The main uncertainties described in the research include that controlled evidence for sustained outcomes is not fully established across all indications, and the documented development of tolerance in some long-term users of the medicine introduces uncertainty regarding maintained symptom control. Further, sample sizes were modest or comparative evidence is lacking for certain patient subgroups. Studies help show what has been observed so far, but research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Key Studies & References Clonazepam Official Drug Monograph and FDA/EMA Clinical Review

Frequently Asked Questions (FAQ)

Common questions about Induzepam (FAQ)

Q: How long does the effect of Induzepam last?

Official product information indicates that Induzepam is classified as a long-acting medicine. The time it takes for half of the drug to be eliminated from the body (the half-life) typically ranges from 30 to 40 hours. This classification indicates the medicine is intended to provide effects sustained over a long period.

Q: Is Induzepam a type of sleeping pill?

Regulatory documents confirm that Induzepam is officially indicated for the management of certain seizure disorders and panic disorder. While it belongs to the benzodiazepine class, which is known to possess sedative properties, its primary approved uses are for neurological stability and managing panic symptoms.

Q: How long does it typically take for Induzepam to start working?

Pharmacokinetic studies show that Induzepam is absorbed quickly into the body. The concentration of the medicine in the bloodstream typically reaches its highest level (the peak) within one to four hours after a dose is taken.

Q: Is Induzepam safe to use every day?

Official warnings address the use of Induzepam over time. Regulatory documents state that using the medicine every day, especially for more than a few weeks, can increase the risk of physical dependence. Official protocols recommend that the medication is gradually reduced if use is discontinued to help minimize withdrawal symptoms.

Q: Can Induzepam affect memory?

Official information lists memory changes as a reported effect. Side effects have included difficulty with thinking, problems concentrating, and temporary memory loss. These effects are often related to the medicine's action on the central nervous system.

Q: Does Induzepam cause weight gain?

Studies conducted during the research phase for Induzepam reported changes in body weight. Both weight gain and weight loss were documented as side effects in some patients, though they were not among the most common adverse reactions listed in the regulatory documents.

Q: Is Induzepam considered a controlled substance?

Yes, Induzepam is classified as a Schedule IV controlled substance by federal regulators. This classification is assigned to medicines that have an accepted medical use but also have a documented potential for misuse, abuse, and dependence, which necessitates strict dispensing controls.

Q: Does Induzepam interact with common pain relievers like ibuprofen?

While official warnings emphasize the risk of combining Induzepam with CNS depressants like opioids, no direct interaction that alters the effect of Induzepam has been specifically identified with common non-opioid pain relievers such as ibuprofen. Official guidance suggests all interaction concerns are discussed with a healthcare professional.

Q: Are there any specific foods I should avoid while on Induzepam?

The medication is processed in the liver by a key enzyme known as CYP3A4. Official documents suggest caution as consuming foods that inhibit this enzyme (like grapefruit or grapefruit juice) could potentially increase drug levels.

Q: Is it safe to drive while taking Induzepam?

Official warnings advise against operating hazardous machinery or driving while taking Induzepam. Regulatory warnings strongly caution patients to avoid attempting such activities until the individual's response to the drug is known, due to the risk of drowsiness, dizziness, and decreased coordination.

Q: How does Induzepam compare to Xanax (Alprazolam)?

Both medicines belong to the benzodiazepine class. However, regulatory classifications distinguish them primarily by their duration of action. Official information classifies Induzepam as a long-acting agent, while medicines like Alprazolam are classified as short-acting agents.

Q: Is Induzepam similar to Valium (Diazepam)?

Induzepam and Diazepam are both benzodiazepines, and both are generally classified as long-acting agents. A key distinction often made in pharmacological profiles is that Induzepam is considered one of the high-potency agents within the benzodiazepine class.

Q: Why is Induzepam sometimes prescribed instead of other similar medicines?

Prescribing decisions are clinical matters, but regulatory documents describe the medicine’s long half-life and its classification as a high-potency benzodiazepine. These properties may contribute to the drug's use in providing a sustained effect for its approved seizure or panic disorder indications.

Q: What should I do if a side effect feels severe?

The Medication Guide and official safety information recommend that individuals experiencing signs of a severe allergic reaction or an overdose seek immediate medical attention. This includes symptoms such as swelling of the face, tongue, or throat, or extreme difficulty breathing.

Q: What is the difference between Induzepam and a regular supplement for sleep?

The key difference lies in the regulatory status of the products. Induzepam is a prescription-only medicine that is classified as a federally controlled substance, and it acts directly on the central nervous system. In contrast, supplements are non-prescription items that are not subject to the same regulatory oversight as prescription drugs.

Q: Can Induzepam affect my heart rate or blood pressure?

Official adverse reaction reports list effects on the cardiovascular system. Side effects have included instances of low blood pressure and reports of heart palpitations. Furthermore, changes in blood pressure and heart rate have been noted during the withdrawal phase when the medicine is being reduced or stopped.

Q: Does Induzepam show up on a standard drug test?

Yes, Induzepam is generally detectable in standard drug screens. Both the parent drug and its primary inactive substance, known as 7-amino-clonazepam, are traceable in biological samples such as urine and blood.

Q: What happens when Induzepam wears off?

When the medicine's concentration in the body decreases, the symptoms it was managing might return. Regulatory warnings emphasize that abruptly stopping the medication may trigger rebound symptoms and serious withdrawal effects, which can include intense anxiety, agitation, and, in severe cases, seizure activity.

Q: What should I tell a new doctor about my Induzepam use?

Official information highlights the importance of disclosing all current medicines and supplements, as well as the full medical history, particularly any history of liver or lung disease, depression, or substance dependence. This disclosure assists the healthcare professional in assessing potential risks and interactions.

Q: Why is Induzepam a prescription-only medicine?

Induzepam is classified as prescription-only due to the significant risks documented in regulatory sources. These risks include the potential for dependence, misuse, and abuse, along with the possibility of serious adverse effects such as respiratory depression. These factors necessitate continuous medical supervision during its use.

Q: Can Induzepam be used for muscle relaxation?

Official product information notes that Induzepam possesses skeletal muscle relaxant properties. In addition to its primary indications, the medicine may be used to help control conditions involving involuntary muscle spasms due to its effect on the central nervous system.

Q: What does the term 'contraindication' mean regarding Induzepam?

The term contraindication, as used in regulatory documents, indicates that the medicine should not be used in a specific situation or with certain medical conditions. This is because the available evidence shows the potential risk of harm to the patient is clearly greater than any expected benefit from the medicine.

Q: Is Induzepam available in generic form?

Yes, the active ingredient in Induzepam, Clonazepam, is available in generic form. Generic versions have been approved by regulatory bodies like the FDA, meaning they have met the required standards for quality and effectiveness.

Q: What if I experience unusual dreams or nightmares while on Induzepam?

Official adverse reaction reports state that unusual changes in sleep activity have been documented. Nightmares and excessive dreaming are reported as rare side effects associated with Induzepam use.

Q: Is Induzepam safe for older adults?

Regulatory documents advise caution when Induzepam is used by older adults. This population may be more sensitive to the drug's effects, particularly drowsiness, confusion, and difficulty with coordination, which can increase the risk of falls.

Q: What is the typical age range for taking Induzepam for seizures?

Official documents state that Induzepam is approved for use in both adults and pediatric patients for certain seizure disorders. Its use in pediatric patients is established, but the dosage requires careful individual determination.

Q: Is the list of side effects in the official documents complete?

Official documents list side effects that were reported during clinical trials and post-marketing surveillance. Regulatory information often includes a disclaimer that the list may not contain every possible reaction, particularly those that occur with a very low incidence.

How should Induzepam be stored and disposed of?

How to Store and Dispose of Induzepam

Official regulatory documents define strict requirements for the storage and disposal of Induzepam to maintain drug quality and safety.

Storage Requirements

Storage Classification Requirement
Temperature Store at controlled room temperature (e.g., 20 C to 25 C).
Protection Protect from light and moisture. Do not freeze.
Packaging Keep in the original container, tightly closed.
Child Safety Must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Induzepam should be disposed of via authorized methods. Government guidelines prohibit flushing the medication down the toilet or pouring it down a drain. Utilize official drug take-back programs, mail-back programs, or approved pharmacy collection points. Disposal must align with local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Induzepam found in:

A-Z Index: